Home
GILD
GILD News

Latest Gilead Sciences Inc. (GILD) News on November 27, 2025

Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock?

Zacks

16 hours ago

Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock?

Gilead snaps up Sprint’s TREX1 immunotherapy programme for $400m

Pharmaceutical Technology

a day ago

Gilead snaps up Sprint’s TREX1 immunotherapy programme for $400m

Is Gilead Sciences Stock Outperforming the Dow?

Barchart

2 days ago

Is Gilead Sciences Stock Outperforming the Dow?

Gilead scoops up a preclinical cancer program

BioPharma Dive

2 days ago

Gilead scoops up a preclinical cancer program

Gilead Foundation Commits Over $3 Million to Address Food Insecurity

Business Wire

3 days ago

Gilead Foundation Commits Over $3 Million to Address Food Insecurity

Investors bet on newer technology and indications for CGTs

Pharmaceutical Technology

3 days ago

Investors bet on newer technology and indications for CGTs

MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC

Zacks

7 days ago

MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC

Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock

Zacks

7 days ago

Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock

Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs

PR Newswire

7 days ago

Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs

Gilead Sciences (GILD): Taking Stock of Valuation as Shares Approach Analyst Targets

Simply Wall St.

7 days ago

Gilead Sciences (GILD): Taking Stock of Valuation as Shares Approach Analyst Targets

Healthcare’s Momentum Gathers Steam. 3 Stocks With Bullish Charts.

Barrons.com

7 days ago

Healthcare’s Momentum Gathers Steam. 3 Stocks With Bullish Charts.

Liver Failure Market Analysis Report 2025-2035: Gilead Sciences, AbbVie, and Boehringer Ingelheim Lead Advancements in Liver Failure Treatments and Artificial Liver Support Technologies

GlobeNewswire

8 days ago

Liver Failure Market Analysis Report 2025-2035: Gilead Sciences, AbbVie, and Boehringer Ingelheim Lead Advancements in Liver Failure Treatments and Artificial Liver Support Technologies

Portal Hypertension Drugs Market Research Report 2025-2035: Key Dynamics, Pipeline Analysis, Regulatory Landscape, Epidemiology

GlobeNewswire

8 days ago

Portal Hypertension Drugs Market Research Report 2025-2035: Key Dynamics, Pipeline Analysis, Regulatory Landscape, Epidemiology

MT Newswires

8 days ago

Gilead Sciences Insider Sold Shares Worth $3,524,173, According to a Recent SEC Filing

MT Newswires

9 days ago

Gilead Sciences Delivers First Shipments of Lenacapavir for HIV Prevention to Eswatini, Zambia

Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa

Business Wire

9 days ago

Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa

Argus Research

10 days ago

Weekly Stock List

Scotiabank Analyst Sees Opportunity in Large Cap Biopharma, Keeps Outperform on GILD

Insider Monkey

11 days ago

Scotiabank Analyst Sees Opportunity in Large Cap Biopharma, Keeps Outperform on GILD

Gilead Sciences, Inc. (GILD)’s Mixed Quarter Draws Divergent Analyst Views

Insider Monkey

12 days ago

Gilead Sciences, Inc. (GILD)’s Mixed Quarter Draws Divergent Analyst Views

GILD's Investigational Regimen for HIV Treatment Meets Primary Goal

Zacks

13 days ago

GILD's Investigational Regimen for HIV Treatment Meets Primary Goal

Is Gilead’s Successful Phase 3 HIV Regimen Trial Shifting the Investment Case for GILD?

Simply Wall St.

13 days ago

Is Gilead’s Successful Phase 3 HIV Regimen Trial Shifting the Investment Case for GILD?

Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal

BioPharma Dive

13 days ago

Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal

MT Newswires

13 days ago

Gilead Sciences Insider Sold Shares Worth $6,590,487, According to a Recent SEC Filing

1 Healthcare Stock to Own for Decades and 2 We Avoid

StockStory

13 days ago

1 Healthcare Stock to Own for Decades and 2 We Avoid

2 Supercharged Dividend Stocks to Buy Now

Motley Fool

14 days ago

2 Supercharged Dividend Stocks to Buy Now

Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

The Fly

14 days ago

Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, AppLovin, Autozone, Booking Holdings, CoreWeave, DoorDash, and More

24/7 Wall St.

14 days ago

Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, AppLovin, Autozone, Booking Holdings, CoreWeave, DoorDash, and More

Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial

Business Wire

14 days ago

Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial

MT Newswires

14 days ago

Scotiabank Initiates Gilead Sciences at Sector Outperform With $140 Price Target

Assessing Gilead After 34% Rally and Recent Pharmaceutical Partnerships

Simply Wall St.

14 days ago

Assessing Gilead After 34% Rally and Recent Pharmaceutical Partnerships

Argus Research

14 days ago

October Lives Up to its Rep

MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress

GlobeNewswire

14 days ago

MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress

Compugen Ltd (CGEN) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

GuruFocus.com

15 days ago

Compugen Ltd (CGEN) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Zacks

15 days ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Gilead Sciences, Moderna, Artivion, Tenet Healthcare, and Charles River Laboratories Stocks Trade Up, What You Need To Know

StockStory

15 days ago

Gilead Sciences, Moderna, Artivion, Tenet Healthcare, and Charles River Laboratories Stocks Trade Up, What You Need To Know

Pulmonary Arterial Hypertension Market Research Report 2025, Competitive Analysis of Gilead Sciences, Viatris, Sandoz, J&J, Sun Pharma, Lupin Pharma, GlaxoSmithKline, Bayer, United Therapeutics

GlobeNewswire

16 days ago

Pulmonary Arterial Hypertension Market Research Report 2025, Competitive Analysis of Gilead Sciences, Viatris, Sandoz, J&J, Sun Pharma, Lupin Pharma, GlaxoSmithKline, Bayer, United Therapeutics

Compugen Reports Third Quarter 2025 Results

PR Newswire

17 days ago

Compugen Reports Third Quarter 2025 Results

MT Newswires

17 days ago

Rothschild & Co Redburn Adjusts Price Target on Gilead Sciences to $153 From $143

Business Wire

17 days ago

AHF’s Mobile Billboard Calls Out Gilead’s Greed at Pharma Summit

How Recent Developments Are Shaping the Gilead Sciences Investment Story

Simply Wall St.

18 days ago

How Recent Developments Are Shaping the Gilead Sciences Investment Story

MT Newswires

19 days ago

Sector Update: Health Care Stocks Ease Late Afternoon

MT Newswires

19 days ago

Sector Update: Health Care Stocks Retreat Friday Afternoon

MT Newswires

19 days ago

Sector Update: Health Care

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Zacks

20 days ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

MT Newswires

20 days ago

Sector Update: Health Care Stocks Mixed Pre-Bell Friday

MT Newswires

20 days ago

Gilead Sciences Says Trodelvy Misses Goal in Post-Endocrine Therapy Breast Cancer Study

MT Newswires

20 days ago

Gilead Sciences Says Long-Term Data Supports Sustained Efficacy, Safety of Primary Biliary Cholangitis Drug

Gilead Provides Update on Phase 3 ASCENT-07 Study

Business Wire

20 days ago

Gilead Provides Update on Phase 3 ASCENT-07 Study

Accipiter Biosciences Emerges from Stealth with $12.7 Million in Seed Financing to Deliver de novo Protein Therapies for Complex Diseases

GlobeNewswire

21 days ago

Accipiter Biosciences Emerges from Stealth with $12.7 Million in Seed Financing to Deliver de novo Protein Therapies for Complex Diseases

Gilead Sciences’s Q3 Earnings Call: Our Top 5 Analyst Questions

StockStory

21 days ago

Gilead Sciences’s Q3 Earnings Call: Our Top 5 Analyst Questions

A Look at Gilead Sciences (GILD) Valuation Following Upgraded Earnings Guidance and Strong Q3 Results

Simply Wall St.

21 days ago

A Look at Gilead Sciences (GILD) Valuation Following Upgraded Earnings Guidance and Strong Q3 Results

Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?

Zacks

22 days ago

Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?

Gilead Sciences to Present at Upcoming Investor Conferences

Business Wire

22 days ago

Gilead Sciences to Present at Upcoming Investor Conferences

HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline

Zacks

23 days ago

HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline

MT Newswires

23 days ago

Argus Research Adjusts Gilead Sciences Price Target to $135 From $130, Maintains Buy Rating

Argus Research

23 days ago

Analyst Report: Gilead Sciences, Inc.

Argus Research

23 days ago

Market Digest: CAH, CVS, GILD, ITRI, MSI, NOC, TROW, ELV, ZION, VTR, TWLO, FOXA

Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025

Business Wire

24 days ago

Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025

Gilead Sciences (GILD) Profit Margin Surge Reinforces Bullish Narratives on Operational Turnaround

Simply Wall St.

a month ago

Gilead Sciences (GILD) Profit Margin Surge Reinforces Bullish Narratives on Operational Turnaround

Closing Bell Movers: Amazon soars to all-time highs on earnings

TipRanks

a month ago

Closing Bell Movers: Amazon soars to all-time highs on earnings

Gilead Stock Reverses; Why Its Buy-Side Miss Isn't The End For Its New HIV Shot

Investor's Business Daily

a month ago

Gilead Stock Reverses; Why Its Buy-Side Miss Isn't The End For Its New HIV Shot

GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow

Zacks

a month ago

GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow

Morningstar Research

a month ago

Analyst Report: Gilead Sciences, Inc.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks

a month ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

MT Newswires

a month ago

Hookipa Pharma Completes Sales of HBV and HIV Assets to Gilead Sciences

GILD Q3 Deep Dive: HIV and Liver Disease Strength Offset Oncology Headwinds

StockStory

a month ago

GILD Q3 Deep Dive: HIV and Liver Disease Strength Offset Oncology Headwinds

Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)

Business Wire

a month ago

Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)

HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead

GlobeNewswire

a month ago

HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead

MT Newswires

a month ago

Goldman Sachs Adjusts Price Target on Gilead Sciences to $110 From $108, Maintains Neutral Rating

MT Newswires

a month ago

Morgan Stanley Adjusts Price Target on Gilead Sciences to $147 From $143, Maintains Overweight Rating

MT Newswires

a month ago

Wells Fargo Adjusts Price Target on Gilead Sciences to $145 From $140, Maintains Overweight Rating

MT Newswires

a month ago

JPMorgan Adjusts Price Target on Gilead Sciences to $150 From $145, Maintains Overweight Rating

MT Newswires

a month ago

RBC Capital Adjusts Price Target on Gilead Sciences to $105 From $100, Maintains Sector Perform Rating

Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks

a month ago

Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say

Gilead Sciences Dives As HIV Drug Misses Bullish Buy-Side Expectations

Investor's Business Daily

a month ago

Gilead Sciences Dives As HIV Drug Misses Bullish Buy-Side Expectations

Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates

Zacks

a month ago

Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates

Gilead Earnings Beat Expectations. The Stock Is Still Falling.

Barrons.com

a month ago

Gilead Earnings Beat Expectations. The Stock Is Still Falling.

Gilead Sciences (NASDAQ:GILD) Exceeds Q3 Expectations

StockStory

a month ago

Gilead Sciences (NASDAQ:GILD) Exceeds Q3 Expectations

MT Newswires

a month ago

Gilead Sciences Q3 Non-GAAP Earnings, Revenue Rise; 2025 Guidance Adjusted

Associated Press Finance

a month ago

Gilead: Q3 Earnings Snapshot

Gilead Sciences Announces Third Quarter 2025 Financial Results

Business Wire

a month ago

Gilead Sciences Announces Third Quarter 2025 Financial Results

Liver Drug Approval and Pipeline Data Could Be a Game Changer for Gilead Sciences (GILD)

Simply Wall St.

a month ago

Liver Drug Approval and Pipeline Data Could Be a Game Changer for Gilead Sciences (GILD)

MT Newswires

a month ago

Gilead Sciences Insider Sold Shares Worth $1,193,926, According to a Recent SEC Filing

Business Wire

a month ago

Victory! AHF, 100 Organizations Kill Gilead’s Greedy Drug Price Hikes

Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?

Zacks

a month ago

Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?

Gilead Sciences (GILD) Reports Q3: Everything You Need To Know Ahead Of Earnings

StockStory

a month ago

Gilead Sciences (GILD) Reports Q3: Everything You Need To Know Ahead Of Earnings

Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline

Zacks

a month ago

Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline

Curious about Gilead (GILD) Q3 Performance? Explore Wall Street Estimates for Key Metrics

Zacks

a month ago

Curious about Gilead (GILD) Q3 Performance? Explore Wall Street Estimates for Key Metrics

3 Value Stocks We Approach with Caution

StockStory

a month ago

3 Value Stocks We Approach with Caution

Gilead Sciences Rallies 32% in 2025 Are Shares Trading Below Their True Value

Simply Wall St.

a month ago

Gilead Sciences Rallies 32% in 2025 Are Shares Trading Below Their True Value

Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?

Zacks

a month ago

Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?

MT Newswires

a month ago

TD Cowen Adjusts Gilead Sciences Price Target to $125 From $115, Maintains Buy Rating

MT Newswires

a month ago

Wolfe Research Adjusts Gilead Sciences Price Target to $140 From $135, Maintains Outperform Rating

Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta

Business Wire

a month ago

Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta

Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know

Zacks

a month ago

Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know

What to Expect From Gilead Sciences' Next Quarterly Earnings Report

Barchart

a month ago

What to Expect From Gilead Sciences' Next Quarterly Earnings Report

LYVDELZI® (SELADELPAR) RECEIVES HEALTH CANADA APPROVAL FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS

CNW Group

a month ago

LYVDELZI® (SELADELPAR) RECEIVES HEALTH CANADA APPROVAL FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS

Business Wire

a month ago

AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP

MT Newswires

a month ago

BMO Capital Adjusts Price Target on Gilead Sciences to $135 From $130, Maintains Outperform Rating

Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025

Business Wire

a month ago

Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025

Share on Social Networks: